Oral budesonide formulations used in treatment of inflammatory bowel disease

Brand names	Type	Description	pH release	Delivery	Uses
Entocort EC (Canada, US) Entocort CR, Entocir (EU, UK) Ortikos (US) NOTE: Generic equivalents may be available	Controlled ileal release (CIR) formulation, pH- and time-dependent	Entocort EC, Entocort CR, Entocir: 3 mg gelatin capsule filled with enteric-coated granules Ortikos: 6 mg gelatin capsule filled with pellets 9 mg gelatin capsule filled with pellets	≥5.5	Terminal ileum and/or ascending colon	Mild to moderately active Crohn of ileum and/or ascending colon
Budenofalk (EU, UK) NOTE: Not available in US or Canada	pH-dependent release	3 mg gelatin capsule filled with enteric-coated granules 9 mg sachet filled with enteric-coated granules	>6.4	Terminal ileum and/or ascending colon	Mild to moderately active Crohn of ileum and/or ascending colon
Uceris (US) Cortiment (Canada, EU, UK)	Multi-matrix (MMX) structure with gastric acid-resistant coating	9 mg delayed- and extended-release tablet	≥7.0	Controlled delivery to ascending, transverse, and descending colon	Mild to moderately active ulcerative colitis

Orally administered budesonide has high presystemic clearance and topical antiinflammatory activity.

EU: European Union; UK: United Kingdom; US: United States.

Adapted from: Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:39.
Additional data from:

US FDA approved drug product information, available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Accessed on September 13, 2017).

Graphic 116034 Version 2.0

خرید پکیج

Oral budesonide formulations used in treatment of inflammatory bowel disease